Chemical Communications, Год журнала: 2024, Номер 60(37), С. 4942 - 4945
Опубликована: Янв. 1, 2024
The triple-mode nanosensor platform developed in this work utilizes fluorescence anisotropy and Förster resonance energy transfer strategies, exhibiting high detection capabilities DNA microRNA analysis.
Язык: Английский
Inorganic Chemistry Communications, Год журнала: 2024, Номер 164, С. 112409 - 112409
Опубликована: Апрель 12, 2024
Язык: Английский
Процитировано
18
Biosensors and Bioelectronics, Год журнала: 2024, Номер 262, С. 116550 - 116550
Опубликована: Июль 6, 2024
Язык: Английский
Процитировано
10
ACS Synthetic Biology, Год журнала: 2025, Номер 14(1), С. 21 - 40
Опубликована: Янв. 6, 2025
The field of healthcare diagnostics is navigating complex challenges driven by evolving patient demographics and the rapid advancement new technologies worldwide. In response to these challenges, biosensors offer distinctive advantages over traditional diagnostic methods, such as cost-effectiveness, enhanced specificity, adaptability, making their integration with point-of-care (POC) platforms more feasible. recent years, aptasensors have significantly evolved in capabilities through emerging microfluidics, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems, wearable devices, machine learning (ML), driving progress precision medicine global solutions. Moreover, advancements not only improve accuracy but also hold potential revolutionize early detection, reduce costs, outcomes, especially resource-limited settings. This Account examines key advancements, focusing on how scientific breakthroughs, including artificial intelligence (AI), improved sensitivity precision. Additionally, has enabled real-time monitoring data analysis, fostering advances personalized healthcare. Furthermore, commercialization aptasensor could increase availability clinical settings support use widespread solutions for health challenges. Hence, this review discusses technological improvements, practical uses, prospects while surrounding standardization, validation, interdisciplinary collaboration application. Finally, ongoing efforts address are ensure that can be effectively implemented diverse systems.
Язык: Английский
Процитировано
2
Nano Letters, Год журнала: 2025, Номер unknown
Опубликована: Янв. 15, 2025
CRISPR/Cas 12a system based nucleic acid and non-nucleic targets detection faces two challenges including (1) multiple crRNAs are needed for biomarkers (2) insufficient sensitivity resulted from photobleaching of fluorescent dyes the low kinetic cleavage rate a traditional single-strand (ssDNA) reporter. To address these limitations, we developed programmable DNA nanoswitch (NS)-regulated plasmonic CRISPR/Cas12a-gold nanostars (Au NSTs) reporter platform with assistance spatial confinement effect. Through simply programming target recognition sequence in NS, only one crRNA is required to detect both biomarkers. The limit decreased by ∼196-fold miRNA-375 122-fold prostate-specific antigen (PSA), respectively. Moreover, versatile evaluation PSA clinical urine samples can also be achieved, according which prostate cancer healthy groups well identified.
Язык: Английский
Процитировано
2
Nucleic Acids Research, Год журнала: 2025, Номер 53(3)
Опубликована: Янв. 24, 2025
Abstract The flexibility and programmability of CRISPR–Cas technology have made it one the most popular tools for biomarker diagnostics gene regulation. Especially, CRISPR–Cas12 system has shown exceptional clinical diagnosis editing capabilities. Here, we discovered that although top loop 5′ handle guide RNA can undergo central splitting, deactivating CRISPR–Cas12a, segments dramatically restore CRISPR function through nucleic acid self-assembly or interactions with small molecules aptamers. This discovery forms basis an engineered Cas12a a programmable proximity-activated (PARC–Cas12a) links targets interest to dsDNA. Leveraging efficient trans- cis-cleavage Cas12, our findings further inspired detection platform design RNAs non-nucleic biomarkers, enabling highly sensitive multiplexed analysis. We demonstrated feasibility RNA-controllable knockout/knockdown in Escherichia coli. Notably, successfully validated regulatory capabilities PARC–Cas12a within mammalian cell systems by utilizing classical theophylline molecule–aptamer system. Our results introduce toolbox precise regulation, allowing development versatile diagnostic tools, complex synthetic biological circuits, cellular biosensors.
Язык: Английский
Процитировано
2
Small, Год журнала: 2025, Номер unknown
Опубликована: Фев. 9, 2025
Late-stage diagnosis is a major contributor to cancer mortality and thus leads increased fatality, making early detection crucial for improving survival rates. Circulating tumor cells (CTC), detectable before primary tumors become clinically apparent, have emerged as vital biomarkers the identification of aggressive cancers. Here, develop single-atom nanozyme integrated nanoarray 3D nano-biointerface ultrasensitive electrochemical screening CTCs from hepatocellular carcinoma. This cytosensor capable identifying CTC at single-cell level, achieving an impressive area under curve 0.96 in receiver operating characteristics, comparable simulated multi-indicator diagnostic strategies. strategy shows great potential non-invasive carcinoma promising be applied universally diagnosis.
Язык: Английский
Процитировано
2
ACS Synthetic Biology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 29, 2025
Advancements in molecular diagnostics, such as polymerase chain reaction and next-generation sequencing, have revolutionized disease management prognosis. Despite these advancements the field faces challenges due to high operational costs need for sophisticated equipment highly trained personnel besides having several technical limitations. The emergent of CRISPR/Cas sensing technology is showing promise a new paradigm clinical although widespread adoption remains limited. This perspective paper discusses specific cases where can surmount existing diagnostic methods by stressing significant role that play revolutionizing diagnostics. It underscores urgency importance addressing technological regulatory hurdles must be overcome harness this effectively laboratories.
Язык: Английский
Процитировано
1
Analytical Chemistry, Год журнала: 2025, Номер unknown
Опубликована: Фев. 11, 2025
The low abundance, complex phenotypes, and need for sophisticated blood preprocessing pose substantial obstacles to the clinical implementation of circulating tumor cells (CTCs). Herein, we constructed a cascaded PMMA chip-based platform separation CTCs from other within samples, as well distinguishing detection epithelial mesenchymal CTCs. primary physical chip (PS-Chip) focused sorted whole via Dean flow fractionation (DFF) according size differences between cells, being capable eliminating approximately 93.7% red (RBCs) 68.4% white (WBCs) while maintaining CTC recovery rate around 90%. Subsequently, further purify isolated in upstream, partitioned immunoaffinity capture (PICD-Chip) featuring with two independent chambers (Zone 1, Zone 2) was designed, each which premodified Gel-GO/E/V-Apt complexes that specifically recognize distinct enabling residual upstream isolation. Upon subsequent introduction probes, namely EpCAM vimentin aptamer-modified mesoporous Pt nanoparticles (mPtNPs/E/V-Apt), into 1 2, respectively, heterogeneous ranging 5 200/mL captured were distinguished quantified utilizing exceptional peroxidase activity mPtNPs. integrated approach efficient enrichment differentiation phenotypic under requirement high purity has enabled successful application diagnosis colon cancer patients at different stages.
Язык: Английский
Процитировано
1
Nanoscale, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Biological barriers significantly impede the delivery of nanotherapeutics to diseased tissues, diminishing therapeutic efficacy across pathologies such as cancer and inflammatory disorders. Although conventional strategies integrate multifunctional designs molecular components into nanomaterials (NMs), many approaches remain insufficient overcome these barriers. Key challenges, including inadequate drug accumulation at target sites nonspecific biodistribution, persist in nanotherapeutic development. NMs, which harness ability precisely modulate spatiotemporally control release kinetics, represent a transformative platform for targeted therapy. In this review, we highlight biological obstacles limiting effective treatment evaluate how stimuli-responsive NMs address constraints. By leveraging exogenous endogenous stimuli, improve specificity, reduce off-target effects, amplify activity within pathological microenvironments. We systematically analyze rational design synthesis driven by advances oncology, biomaterials science, nanoscale engineering. Furthermore, NM classes-including polymeric, lipid-based, inorganic, hybrid systems explore functionalization using targeting ligands, antibodies, biomimetic coatings. Diverse are evaluated, small-molecule prodrug activation, peptide- protein-based targeting, nucleic acid payloads, engineered cell-mediated transport. Despite promise challenges biocompatibility, scalable fabrication, clinical translation must be addressed. elucidating structure-function relationships refining stimulus-triggered mechanisms, pave way precision oncology strategies, enabling patient-specific therapies with enhanced safety. This interdisciplinary insights aims catalyze innovation next-generation nanomedicine treatment.
Язык: Английский
Процитировано
1
Biosensors and Bioelectronics, Год журнала: 2025, Номер 279, С. 117373 - 117373
Опубликована: Март 12, 2025
Язык: Английский
Процитировано
1